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Abstract
Background: Cognitive dysfunction affects up to 70% of people with progressive MS (PMS). It can exert a
deleterious effect on activities of daily living, employment and relationships. Preliminary evidence suggests that
performance can improve with cognitive rehabilitation (CR) and aerobic exercise (EX), but existing data are
predominantly from people with relapsing-remitting MS without cognitive impairment. There is therefore a need to
investigate whether this is also the case in people with progressive forms of the disease who have objectively
identified cognitive impairment. It is hypothesized that CR and EX are effective treatments for people with PMS
who have cognitive impairment, in particular processing speed (PS) deficits, and that a combination of these two
treatments is more effective than each individual treatment given alone. We further hypothesize that improvements
in PS will be associated with modifications of functional and/or structural plasticity within specific brain networks/
regions involved in PS measured with advanced MRI techniques.
Methods: This study is a multisite, randomized, double-blinded, sham controlled clinical trial of CR and aerobic
exercise. Three hundred and sixty subjects from 11 sites will be randomly assigned into one of four groups: CR plus
aerobic exercise; CR plus sham exercise; CR sham plus aerobic exercise and CR sham plus sham exercise. Subjects
will participate in the assigned treatments for 12 weeks, twice a week.
All subjects will have a cognitive and physical assessment at baseline, 12 weeks and 24 weeks. In an embedded
sub-study, approximately 30% of subjects will undergo structural and functional MRI to investigate the neural
mechanisms underlying the behavioral response. The primary outcome is the Symbol Digit Modalities Test (SDMT)
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measuring PS. Secondary outcome measures include: indices of verbal and non-verbal memory, depression, walking
speed and a dual cognitive-motor task and MRI.
Discussion: The study is being undertaken in 6 countries (11 centres) in multiple languages (English, Italian, Danish,
Dutch); with testing material validated and standardized in these languages. The rationale for this approach is to
obtain a robustly powered sample size and to demonstrate that these two interventions can be given effectively in
multiple countries and in different languages.
Trial registration: The trial was registered on September 20th 2018 at www.clinicaltrials.gov having identifier
NCT03679468. Registration was performed before recruitment was initiated.
Keywords: Aerobic exercise, Cognitive training, Progressive multiple sclerosis
Background
A recent comprehensive review of rehabilitation studies in
progressive MS (PMS) encompassing balance, weakness,
cardiovascular fitness, ataxia, fatigue, bladder dysfunction,
spasticity, pain, cognitive deficits, depression and pseudo-
bulbar affect concluded that there was a striking dearth of
studies devoted solely to people with secondary progressive
MS (SPMS) or primary progressive MS (PPMS) [1]. Fur-
thermore, when including progressive patients alongside
patients with relapsing-remitting disease (RRMS), subject
numbers has generally been very small while analysis of
treatment effects have not accounted for the possible influ-
ence of disease course. Finally, in the few studies reporting
benefits of treatment for patients with progressive disease,
the ecological validity of the results remained uncertain.
The present study focuses on improving cognition in
people with PMS for two reasons.
First, up to 70% of people with PMS are impaired in
this domain [2] and second, people with MS have them-
selves identified cognitive dysfunction as a primary area
of concern [3]. Furthermore, there are now a number of
studies suggesting that cognitive rehabilitation (CR) can
result in significant improvements in numerous cogni-
tive domains. A consistent picture is emerging of CR
bringing about improvements in learning/memory [4, 5]
and processing speed [6, 7]. Of note is that home-based
CR programs have also reported significant cognitive
gains [8, 9] as have interventions administered in a
group setting [10, 11]. Complementing these data are
findings suggesting that exercise too can provide phys-
ical, cognitive and emotional benefits [12–14].
These results, while encouraging, are also limited by
various factors including small sample size, single centre
administration and sample composition predominately
limited to people with RRMS. Whether people with pro-
gressive disease will derive the same benefits from these
interventions is therefore not known, although a single
study suggests that improvement in memory may be
possible with CR [4]. The gaps in our knowledge there-
fore suggest a number of complementary ways forward.
Multisite replication of these preliminary, promising
findings is a good place to start. However, as people with
progressive MS constantly remind us, time is short. This
suggests that an additional effort is required, a bolder
approach, one that combines more than one interven-
tion with the aim of producing synergistic effects, an im-
provement in one area boosting the putative benefits of
therapy in another, the overall outcome exceeding the
sum of the individual treatments. Such an approach
often reflects the clinical reality of PMS where multiple
neurological difficulties rather than an isolated problem
must be addressed simultaneously. While a powered
joint CR and exercise clinical trial has yet to be done in
people with MS of any disease course there is tentative
evidence from three small studies in people with RRMS
that this approach may be more beneficial than either
intervention alone [15–17]. Thus, a methodologically
rigorous, well-powered study is needed now in PMS spe-
cifically in an effort to inform clinical practice. It is only
through such a study that we can ensure that final con-
clusions and recommendations are not limited by sam-
ple size, generalizability or methodological concerns.
Methods/design
The protocol adheres to the Spirit guidelines.
Aim, design and setting of the study
The study has the following primary aims:
1. To assess whether CR and exercise (EX) in
combination have beneficial synergistic effects in
the treatment of impaired processing speed in
people with PMS.
2. To determine whether CR and EX are individually
effective treatments for impaired processing speed
in people with PMS.
Secondary aims:
1. To assess the everyday life impact of cognitive and/
or physical changes after the different rehabilitation
interventions.
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2. To assess brain functional and structural substrates
of cognitive changes after the different
rehabilitation interventions.
This study is a multicenter, multi-arm, randomized,
double-blinded, sham-controlled trial that includes fol-
low up periods of 12- and 24 weeks (+/− 2 weeks) post
randomization. As depicted in Fig. 1, after the baseline
assessment each participant will be randomized to one
of four arms with different combinations of CR and EX
and their respective shams (−S). That is: CR + EX; EX +
CR-S; EX-S + CR; EX-S + CR-S.
The study protocol will be carried out at 11 sites in six
different countries (Canada (1 site), USA (2 sites), United
Kingdom (2 sites), Denmark (1 site), Belgium (1 site) and
Italy (4 sites)). Each site has at least one blinded and one
unblinded research assistant. The blinded measurement
assessor (research assistant) will screen potential partici-
pants and perform all baseline and 6-month testing,
whereas the 3-month follow up interview will be made by
the unblinded research assistant. If a participant meets the
inclusion criteria (see later), the unblinded research assist-
ant is responsible for randomizing participant using RED-
Cap (a web-based system) and conducting the
interventions for which the participant is assigned. As the
study design aims to mask the intent of the intervention
given to the participants, the unblinded research assistant
will be strictly instructed not to discuss participant alloca-
tion and participants will likewise be instructed not to re-
veal details that can indicate their group allocation to the
blinded assessor. The MRI analysis will be undertaken by
experienced technicians blinded to group allocation.
Fig. 1 Study flow-chart. RRMS, Relapsing-Remitting Multiple Sclerosis; EDSS, Expanded Disability Status Scale; CNS, Central nervous system; PMS,
Progressive Multiple Sclerosis; GLTEQ, Godin Leisure-Time Exercise Questionnaire; BDI-II Beck Depression Inventory-II; SDMT, Symbol Digit
Modalities Test; CR-S, cognitive rehabilitation - sham; EX-S, exercise-sham; EX, exercise; CR, cognitive rehabilitation
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Recruitment and screening of participants
Participants are being recruited via specialized in and
out-patient MS clinics, as well as via media advertising.
Prior to enrollment, all potential participants will
undergo a two-step screening procedure. First, a pre-
screening examination in person or via telephone will
collect basic information. If the participant passes the
initial pre-screen, a detailed face-to-face screening for
neurological, psychiatric, cognitive, and medical variables
will take place at the participating center. Inclusion and
exclusion criteria for the two screening steps are sum-
marized in Tables 1 and 2, respectively.
When participants complete the study they will revert
to their neurologist and usual care programs.
Randomization
Participants will be randomized to a treatment arm
using block randomization by site. Block sizes will be
blinded to study personnel and principal investigators.
Randomization assignment will be conducted in RED-
Cap (a secure web application for building and managing
databases) within 24 h after the baseline assessment.
Interventions
For all interventions, comprehensive manuals were de-
veloped and distributed to all participating sites to en-
sure optimal standardization. This was complemented
by face-to-face and distance training at the beginning of
the study, and supplemented as necessary during the
course of the study. All interventions will be delivered
within the hospital/clinic setting or research center
under individual supervision, twice per week over a 12
week period. All intervention sessions will start with ei-
ther CR or CR-S followed by EX or EX-S. In case of
holiday, sickness or other unforeseen circumstances the
intervention period may be extended by up to two add-
itional weeks, allowing the intervention period to be a
maximum of 14 weeks. During the intervention period,
compliance to the exercise prescription (attended/
planned sessions; actual intensity/target intensity; actual
duration/target duration) and cognitive rehabilitation
protocols will be monitored by an independent person
who will provide regular feedback to sites to optimize
the fidelity of the treatment regimens.
Any potential reason for discontinuing will be dis-
cussed on individual basis between the principal investi-
gator of the site and the Data Safety Monitoring Board.
If a situation occurs where precaution has to be taken in
order for the participant to continue in the study,
unblinding will be permissible if permitted by the study
steering committee.
Cognitive rehabilitation (CR)
The CR component comprises the computerized Reha-
Com program (Pearson’s Clinical Assessment group,
Bloomington, MA, USA) that will be performed on non-
consecutive days. To address processing speed, the mod-
ules “divided attention 1 and 2”, “attention and control”,
“sustained attention” and “vigilance 2” will be used. Par-
ticipants will begin at level 1 and advance the program
as dictated by their performance. Each session will be
programmed to last 45 min. The RehaCom program has
previously been shown to have positive effects on pro-
cessing speed in persons with RRMS [6, 8, 18].
Sham cognitive rehabilitation (CR-S)
The CR-S consists of Internet training [19], beginning
with more basic tasks such as learning to use a computer
Table 1 Inclusion and exclusion criteria for the initial pre-screening step
Inclusion criteria
Diagnosis A definite diagnosis of PMS determined by neurologist
Age 25–65 years
Ambulation Not wheelchair dependent (EDSS,< 7.0)
Exclusion criteria
Substance abuse Use of illicit drugs, PCP, LSD, Stimulants,
Amphetamines, Barbiturates, etc. (Cannabis use is accepted).
Neurological history Relapses in the past 3 months, a history of central nervous system disease other than
PMS such as stroke, Parkinson’s disease, traumatic brain injury, etc.
Severe mental illness Psychotic symptoms, Bipolar Disorder, Schizophrenia.
Medications Steroid use within the past 3 months.
Transport Unable or unwilling to travel to the center for testing and training or requiring transportation by ambulance.
Medical contradiction No medical clearance provided by a physician upon failure of AHA/ACSM Health/Fitness Facility Pre participation
Screening Questionnaire.
Current exercise activity Currently performing enough physical activity for health benefits based a GLTEQ score > 23).
PCP Phencyclidine, LSD Lysergic acid diethylamide, AHA American Heart Association, ACSM American College of Sports Medicine, EDSS Expanded Disability Status
Scale, GLTEQ Godin Leisure-Time Exercise Questionnaire, PMS Progressive Multiple Sclerosis
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and the internet to search for information, including lo-
cating information regarding medications, gardening,
getting directions, etc. Each session is programmed to
last 45 min and will also take place on non-consecutive
days. The control session is designed to match the CR
on social and computer contact. Similar training proce-
dures have previously been shown not to impact PS in a
normal aging sample [19].
Exercise (EX)
The exercise intervention is aerobic and performed on a
recumbent stepper (NuStep T5XR, Ann Arbor, MI,
USA). All sessions are supervised and performed on an
individual basis. Training is performed on non-
consecutive days thereby permitting recovery between
sessions. The EX intervention consists of twice weekly
sessions, one of which is continuous exercise and the
other of which is high intensity interval training. It com-
plies with the basic principle of progressive overload.
The continuous training ranges from 10min of exercise
at a work rate corresponding with 50–60% of VO2peak
at week one, progressing to 30min of exercise at a work
rate corresponding with 70–80% of VO2peak in week 12.
The interval training begins with 5 × 1min of exercise at
a work rate corresponding with 80–90% VO2peak
followed by 1 min of active breaks with a work rate at 15
watts. At week 12 the protocol will have progressed to
10 × 2min of exercise at a work rate corresponding with
90% VO2peak followed by 2 min of active breaks with a
work rate of 15 watts. Protocols built on the same prin-
ciples have previously improved VO2peak in persons
with MS [20, 21]. The recumbent stepper represents an
acceptable modality of aerobic exercise in people with
PMS [22] as has interval training using this device. See
Table 3 for further details.
Sham exercise (EX-S)
The EX-S does not put strain on the cardiovascular sys-
tem, so as to avoid a potential aerobic effect, and avoids
incorporating progressive resistance strengthening (the
use of weights are not permitted) as improvement in
aerobic capacity [23] and lower limb muscle strength
[24] have been associated with faster cognitive process-
ing speed. Moreover, no focused dual task activities are
performed during the training sessions, so as to avoid
any potential cognitive training. Hence the EX-S is fo-
cusing on balance, co-ordination and stretching, which
is a credible sham exercise comparator.
The EX-S sessions have been designed to reflect the
EX intervention for time and attention, hence the fre-
quency and duration of sessions, and the manner in
which the training times progress throughout the 12
week program mimic that described above. During all
EX-S sessions at least one exercise from each of six
different categories is performed to allow variation;
these are selected on the basis of individual need (ex-
ercises summarized in Table 4). To ensure that exer-
cises are at a light intensity, heart rate and rate of
perceived exertion (RPE) are monitored throughout
the training sessions, after completion of each exer-
cise (i.e. a minimum of six times). Should either the
HR or RPE increase above pre-set criteria, an
enforced rest is required by the participant to prevent
any potential aerobic effect of the exercise. The EX-S
protocol builds on a sham intervention that was ap-
plied in a previous study in people with MS [25].
Follow up
To encourage people to continue exercising post super-
vision the goals of the person with MS will be discussed
and taken into account at the beginning of the program,
and then reviewed on a further three occasions (every 4
weeks) during the 12 week intervention. This is a prac-
tical, and commonly used strategy for positively affecting
behavioral change and engagement with rehabilitation
programs [26].
Study status
By March 2020, a total of 135 participants have been
randomized into the study. Of these, 40 are now in the
intervention phase, 90 have completed the immediate
Table 2 Inclusion and exclusion criteria for the second in-person interview
Inclusion Criteria
SDMT 1.282 SD or more below published normative data (10th percentile).
Exclusion criteria
Visual Acuity Corrected near vision worse than 20/70 (to see the test materials).
Severe nystagmus according to neurologist ratings.
The Beck Depression
Inventory
Score≥ 29 (indicative of severe depression)
Token test Score≥ 29 indicative of intact verbal comprehension
MRI sites only Failing the standard MRI screening form
MRI Magnetic Resonance Imaging, SDMT Symbol Digit Modalities Test
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follow up, 63 have completed the 3-month follow up
and 37 have completed the 6-month follow up.
Outcomes and assessments
Primary outcome
The primary outcome of this study is the change in pro-
cessing speed (PS) over the 12weeks of training, assessed
with the Symbol Digit Modalities Test (SDMT). The
SDMT is available in several versions, and in the present
study, 3 versions will be used in a randomized order to
minimize practice effects when repeated [27]. There are
several reasons why we chose PS as the primary outcome
measure. First, it is well known that PS is the primary cog-
nitive impairment in persons with MS [28] and as a pri-
mary cognitive construct, impaired PS itself can lead to
problems in higher cognitive functioning such as executive
Table 3 The progressive aerobic exercise protocol
Week Session 1 (Continuous training; CT) Session 2 (High Intensity Interval Training; HIIT)
1 CT (10 min @ WR ~ 50–60% VO2peak) HIIT (5, 1:1 work:rest intervals; work for 1 min @ WR
~ 80–90% VO2peak, rest for 1 min at 15 W)
2 CT (15 min @ WR ~ 50–60% VO2peak) HIIT (5, 1:1 work:rest intervals; work for 1.5 min @ WR
~ 80–90% VO2peak, rest for 1.5 min at 15 W)
3 CT (20 min @ WR ~ 50–60% VO2peak) HIIT (5, 1:1 work:rest intervals; work for 2 min @ WR
~ 80–90% VO2peak, rest for 2 min at 15 W)
4 CT (25 min @ WR ~ 50–60% VO2peak) HIIT (6, 2:2 work:rest intervals; work for 2 min @ WR
~ 80–90% VO2peak, rest for 2 min at 15 W)
5 CT (30 min @ WR ~ 50–60% VO2peak) HIIT (7, 2:2 work:rest intervals; work for 2 min @ WR
~ 80–90% VO2peak, rest for 2 min at 15 W)
6 CT (30 min @ WR ~ 50–60% VO2peak) HIIT (8, 2:2 work:rest intervals; work for 2 min @ WR
~ 80–90% VO2peak, rest for 2 min at 15 W)
7 CT (30 min @ WR ~ 60–70% VO2peak) HIIT (9, 2:2 work:rest intervals; work for 2 min @ WR
~ 80–90% VO2peak, rest for 2 min at 15 W)
8 CT (30 min @ WR ~ 60–70% VO2peak) HIIT (10, 2:2 work:rest intervals; work for 2 min @ WR
~ 80–90% VO2peak, rest for 2 min at 15 W)
9 CT (30 min @ WR ~ 65–75% VO2peak) HIIT (10, 2:2 work:rest intervals; work for 2 min @ WR
~ 90% VO2peak, rest for 2 min at 15 W)
10 CT (30 min @ WR ~ 65–75% VO2peak) HIIT (10, 2:2 work:rest intervals; work for 2 min @ WR
~ 90% VO2peak, rest for 2 min at 15 W)
11 CT (30 min @ WR ~ 70–80% VO2peak) HIIT (10, 2:2 work:rest intervals; work for 2 min @ WR
~ 90% VO2peak, rest for 2 min at 15 W)
12 CT (30 min @ WR ~ 70–80% VO2peak) HIIT (10, 2:2 work:rest intervals; work for 2 min @ WR
~ 90% VO2peak, rest for 2 min at 15 W)
WR Work rate, CT Continuous training, HIIT High intensity interval training
Table 4 Exercise categories of the sham treatment and the subsequent exercise selection of each category
Type 1:
Stretches
Type 2:
Exercises in crook lying
Type 3:
Exercises in side lying
a) Hamstrings
b) Quadriceps
c) Hip Flexors
d) Hip Abductors
e) Bilateral hip abductor
f) Ankle plantar-flexors
a) Bridging (two legs/single leg)
b) Trunk rotation
c) Pelvic tilt
d) Unilateral hip abduction/
bilateral hip abduction
e) Hip and knee
flexion/extension
a) unilateral hip abduction
b) unilateral hip abduction/
lateral rotation
c) Unilateral knee
flexion/extension
Type 4:
Exercises in prone
Type 5:
Exercises in unsupported sitting
Type 6:
Exercises in standing
a) Unilateral hip extension
b) Unilateral/bilateral knee flexion
c) Bilateral isometric
gluteal contractions
d) Unilateral/bilateral hip rotation
a) Anterior/posterior pelvic tilt
b) Trunk rotation
c) Forward trunk flexion
d) Unilateral trunk extension
(reach out of base of support)
e) Unilateral knee extension/flexion
f) Unilateral hip abduction
g) Bilateral hip abduction
a) Squats (two legs/single leg)
b) Step-ups onto low step
c) Balancing on one leg
(single-leg stance)
d) Sideways stepping
e) Backwards stepping
f) Balancing in step-stance
g) Lateral reaching out of base of support
[25]
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abilities [29]. As such, improving PS may also improve
other cognitive areas. Second, there is good preliminary
data from smaller studies from multiple laboratories that
both CR and exercise improve PS [24, 30–32]. Third, the
existing RehaCom literature shows the most consistent and
significant effect on PS [18, 33–36]. Fourth, a recent topical
review of the SDMT found strong evidence supporting the
reliability and validity of the test and recommended a re-
sponder definition of SDMT change approximating 4
points or 10% in magnitude [37]. Lastly, after an extensive
review of potential cognitive outcome measures by the
Multiple Sclerosis Outcome Assessment Consortium, the
SDMT was recommended to the Federal regulators as the
cognitive test of choice to be included in MS clinical trials
[38].
Secondary outcome
All secondary outcomes will be assessed during the in-
person interview or the baseline assessment, at the post
12-week assessment and at the 24-week follow-up
assessment.
Study assessments
Study assessments are composed of the neuropsycho-
logical and exercise assessments, MRI, and the comple-
tion of the patient reported outcomes (PROs).
For a detailed overview of all outcomes and the timing
of assessment see Table 5.
Neuropsychological evaluation
This is conducted in one session to document current
levels of cognitive performance. The neuropsychological
assessment includes a standard, widely accepted assess-
ment battery for MS, the BICAMS [39]. The BICAMS
consists of our primary outcome measure, the SDMT, as
well as two other cognitive tests of verbal and visual learn-
ing and memory that will be used as secondary outcome
measures, namely the California Verbal Learning Test
(CVLT) and the Brief Visuospatial Memory Test (BVMT-
R). The BICAMS is available in the languages represented
within our study sample (English, Italian, French, Dutch
and Danish). Language specific normative data are avail-
able in all cases [40–43] except in the case for Denmark,
where the Dutch norm-data will be applied. Z-scores
computed for inclusion criteria used regression-based
norms adjusting for linear and non-linear age, sex and
total years of education for either the raw or scaled scores
from the respective normative data. To provide an assess-
ment of cognitive reserve the Wechsler Test of Adult
Reading (WTAR) [44] will be administered at baseline.
The WTAR is validated in the participant’s primary lan-
guage, and an estimated IQ will be computed based on
performance. This estimated IQ score will serve as a com-
mon metric across all participants for inclusion in
analyses. For those countries which do not have WTAR
data, the comparable Adult National Reading Test (ANAR
T) [45] will be used.
Physical performance
Height and weight will be used to calculate the Body
Mass index (BMI). An incremental cardiopulmonary ex-
ercise test (CPET) will be conducted to assess peak aer-
obic capacity and power using the recumbent stepper
that is also used for the exercise intervention. The incre-
mental CPET will be undertaken in a standardized man-
ner, and with scripted instructions to the participant.
Expired gases will be collected using a 2-way non-
rebreathable valve (e.g. Hans Rudolph, Kansas City, MO,
USA or the like) and oxygen consumption will be con-
tinuously measured using an open circuit spirometry
system (e.g. TrueOne, Parvo Medics, Sandy, UT, USA or
similar). Participants will complete a 1-min warm-up at
15W. The initial work rate will be set to 15W and grad-
ually increase until the participant reaches volitional fa-
tigue. The work rate will be increased by 10W per
minute or 5W per minute for participants with mild to
moderate (i.e., EDSS of 4.0–5.5) or severe disability (i.e.,
EDSS of > 6.0), respectively. Participants will be encour-
aged to maintain a stepping rate of 60–100 steps per mi-
nute throughout the test depending on the work rate.
Heart rate (Polar FT1 Heart Rate Monitor, Polar Electro
Inc., Bethpage, NY, USA), and Ratings of Perceived Ex-
ertion (RPE) via the Borg Rating of Perceived Exertion
Scale will be recorded every minute. The highest re-
corded 20-s rate of oxygen consumption value (VO2)
will be recorded as peak oxygen consumption
(VO2peak), expressed in mL/kg/min, optimally when
two or more of the following criteria is satisfied: (1) re-
spiratory exchange ratio (RER) of 1.10 or greater; (2)
peak heart rate within 10 beats per minute of age-
predicted maximum (i.e., 220-age); or (3) RPE of 17 or
greater. The highest recorded power achieved during a
20-s period will be recorded as peak power output
(Wpeak). This CPET protocol has previously been used
in persons with MS [46], and will be used for measuring
changes in aerobic capacity and for prescribing the re-
cumbent stepper exercise training sessions [21].
Walking performance will be assessed by the 6 min
walk test (6MWT). Subjects will be instructed to walk at
their fastest speed, and to cover as much distance as
possible, according to the script of Goldman et al. [47].
Subjects will be notified, without further encouragement,
about each expired minute. Distances walked per minute
and total distance will be recorded. Subjects walk back
and forth along a 30-m hallway turning around cones at
each end. In centers without this facility, a square trajec-
tory is allowed given that this has been shown not to
compromise results [48].
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Table 5 Overview of assessments at different test-sessions
Outcome Initial Screening In person
Screening
Baseline
Assessment
12-week
intervention
Immediate
Post 12-week
Assessment
3-months follow-
up Interview
6-months follow-up
Assessment
Cognitive
BICAMS*
SDMT X X X
Token Test X
BICAMS*
CVLT X X X
BICAMS*
BVMT-R X X X
WTAR or NART X
Physical
Visual Acuity test X
ActiGraph Device X X**
CMI X X X
6MWT X X X
IET X X X
Functional MRI*** X X X
PRO´s
Fitness Questionnaire**** X
GLTEQ X
Demographic form X
BDI-II X
FAMS X X X
EQ-5D-5L X X X
MSIS-29-V2 X X X
MSWS-12 X X X
PDQ-20 X X X
MFIS X X X
HADS X X X
Customized
Phone Interview X
Consent form X
Medication list X X X
Goal Setting Sheet X
Adverse Event form***** X
Post Intervention Interview X
Post Intervention Survey X
Serious Adverse Event form***** X
*Available in three parallel versions;** measured during the week following the intervention; ***only performed at 3 sites; **** AHA/ACSM Health/
Fitness Facility Pre participation Screening Questionnaire *****only completed if necessary
Abbreviations: BICAMS Brief International Cognitive Assessment for MS, SDMT Symbol Digit Modalities Test, CVLT California Verbal Learning Test, BVMT-R
Brief Visuospatial Memory Test-Revised, WTAR Wechsler Test of Adult Reading, NART National Adult Reading Test, CMI Cognitive-Motor Interference,
6MWT Six Minute Walk Test, IET Incremental Exercise Test, Functional MRI Functional Magnetic Resonance Imaging, GLTEQ Godin Leisure-Time Exercise
Questionnaire, BDI-II Beck Depression Inventory-II, FAMS Functional Assessment of Multiple Sclerosis, EQ-5D-5L European Quality of Life-5 Dimensions,
MSIS-29 V2 Multiple Sclerosis Impact Scale-29 Items Version2, MSWS-12 Multiple Sclerosis Walking Scale 12 Items, PDQ-20 Perceived Deficits
Questionnaire 20 Items, MFIS Modified Fatigue Impact Scale, HADS Hospital Anxiety and Depression Scale
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Cognitive-motor interference during walking will be
quantified by a dual task cost (DTC) calculation in the
motor and cognitive domains. The DTC calculation is
based on a comparison of the performance on a single
motor or cognitive task and the motor and cognitive
performance during a concurrent motor plus cognitive
dual task. The formula is DTC = ((DT-ST)/ST)*100.
There are data suggesting that this dual modality testing
can give additional insights into the putative benefits of
the proposed interventions [49–51]. The single motor
task requires the participant to walk at the fastest pos-
sible speed while maintaining safety for 60 s. The dis-
tance covered is measured. The setting for the 6MWT
(30m corridor) will be used for this test. The single cog-
nitive task entails performing the alternating Latin al-
phabet for 60 s [52]. During the task, subjects list
alternating letters of the alphabet as fast and accurately
as possible (i.e., A, C, E, G, etc.). The number of correct
letters provided by the subjects is recorded. The test re-
quires working memory and inhibitory control. The
cognitive-motor dual task involves walking at fast speed
for 60 s with the alternating alphabet test as a concur-
rent task. Subjects will be instructed to divide attention
equally on walking while correctly naming alternating
letters of the alphabet.
Physical activity will be determined by accelerometry.
Participants will wear the accelerometer (Actigraph;
http://actigraphcorp.com/) on an elastic belt around the
waist located above the non-dominant hip during the
waking hours for 7 days before the first intervention
week and during the week following completion of the
intervention. This method has proven reliable in people
with MS [53]. It will provide data on the degree of life-
style physical activity (i.e. steps/day and minutes/day of
moderate to vigorous physical activity) immediately be-
fore and after the intervention phase.
Patent reported outcomes (PRO’s)
PRO’s include the HADS, BDI-II, MFIS and PDQ. The
MSWS-12, MSIS-29 version 2 and EQ-5D-5L are all
standardized self-report outcome measures having
strong reliability and validity in people with MS [54, 55]
and with evidence supporting their responsiveness in re-
habilitation trials [55–57]. Their wide use in MS inter-
ventional studies will enable comparisons between
studies. The MSWS-12 provides information on the sub-
jective impact of MS on walking and related activities
and therefore adds important information regarding
what can be obtained from objective measures of walk-
ing. Furthermore, it has strong psychometric properties
[58]. The MSIS-29 is a disease specific measure of the
impact of MS; it has a preference-based tariff [59] for
use in sensitivity analyses for the Quality Adjusted Life
Year (QALY) outcome, and has been endorsed for use in
health economic analyses in MS studies [60]. This will
complement the EQ-5D-5L, which is recommended for
use in health policy decision making [60]. The FAMS
was specifically developed for use with the MS popula-
tion and has been shown to have adequate reliability and
validity within this population. The measure contains 59
questions organized into 6 subscales: mobility, symp-
toms, emotional well-being, general contentment, think-
ing/fatigue, and family/social [61]. The thinking/fatigue
subscale is composed of 9 items, including questions
pertaining to task initiation, task completion, new learn-
ing, memory, concentration, and slowness of thought.
Participants rate their symptoms on a 5-point Likert
type scale. This assessment focuses on the person as a
whole, investigating impairments, functional limitations,
and disability in many areas of the person’s life. This
overview of functional status at all levels is important in
determining the impact of cognitive treatment on an in-
dividual’s everyday life. The FAMS has demonstrated
good internal consistency, reliability and validity [61].
The scale has been used successfully to measure change
from before to after cognitive rehabilitation [62]. To pro-
vide an assessment of anxiety and depression at each as-
sessment, the Hospital Anxiety Depression Scale
(HADS) [63] will be administered. The Modified Fatigue
Impact Scale (MFIS) [64] will additionally be adminis-
tered to assess fatigue at each assessment. Subjective
cognitive deficits will be assessed with the Perceived
Deficits Questionnaire (PDQ) [65].
Brain MRI protocol
Brain MRI scans will be obtained using 3.0 Tesla scan-
ners. Budgetary constraints dictate that the MRI is ob-
tained in one third of the sample (i.e. 120 subjects
divided equally (n = 30) between the four treatment
arms). The following sequences will be collected at base-
line, termination of the interventions and after 24 weeks
of follow up, following a standardized protocol of acqui-
sition and careful guidelines for patients repositioning:
axial T2 weighted Turbo Spin Echo (TSE); axial FLAIR;
high resolution 3D sagittal T1-weighted sequence; axial
DT sequence (55 contiguous, 2.5 mm thick, slices, #DW
direction = 64) and T2*-weighted single-shot echo-
planar imaging (EPI) during and active cognitive fMRI
task and at rest.
For active fMRI, the Go/No-go task will be adminis-
tered using a block-design, as previously described [66].
Reaction times, omission errors (no response although
required), commission errors (false response without ad-
equate cue), and the proportion of correct responses will
be recorded using a response-box. Before imaging, par-
ticipants will be familiarized with the paradigm. The
fMRI Go/no-Go paradigm has been used both in cross-
sectional [67] and longitudinal [68] studies of people
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with MS. Notably, a longitudinal (median follow up 20
months) neuropsychological and fMRI evaluation de-
tected significant correlations between worsening of
SDMT performances and modification of activation dur-
ing the Go/no-Go task in several supra- and infratentor-
ial brain regions [68]. Most importantly, the Go/no-Go
task has already been validated for multicentric acquisi-
tion [66]. During resting state (RS) fMRI, subjects will be
instructed to remain motionless, to close their eyes and
not to think about anything in particular. Movements
will be minimized using foam padding and ear blocks.
The total duration of MRI acquisition (structural plus
functional MRI) will be approximately 50 min.
MRI analysis: MRI data acquired for the study will be
analyzed centrally at one Neuroimaging Research Unit
(Hospital San Raffaele, Milan, Italy).
Lesion and atrophy analysis: Brain T2-hyperintense
and T1-hypointense lesion volumes (LV) will be mea-
sured on FLAIR and 3D T1-weighted scans, respectively,
using a local thresholding segmentation technique (Jim
7.0, Xinapse Systems, West Bergholt, UK). New lesions
at follow-up will be counted. Normalized brain (NBV),
WM (WMV) and GM (GMV) volumes will be measured
on 3D T1-weighted scans using the SIENAx software,
after T1-hypointense lesion refilling.168 Hippocampal
volume will be estimated using FIRST software.
Mapping changes in gray matter (GM) and white mat-
ter (WM) structures: Voxel-based Morphometry (VBM)
with DARTEL method will be applied to determine
between-group differences of GM volumes at baseline,
using SPM12 and 3D T1-weighted images. Tensor-based
Morphometry (TBM) [69] will be applied to map the
longitudinal regional variations of GM volume at the dif-
ferent time points.
Diffusion-weighted images will be corrected for
distortions induced by the eddy currents and for
head movements, and transformed to MNI (Montreal
Neurological Institute) space. Then, using the
FMRIB’s Diffusion Toolbox (http://www.fmrib.ox.ac.
uk), the DT will be estimated in each voxel by linear
regression [70] and mean diffusivity (MD), radial dif-
fusivity (RD), axial diffusivity (AD) and fractional an-
isotropy (FA) maps derived. Tract-based Spatial
Statistics (TBSS) will be used to define the patterns
of microstructural WM abnormalities on diffusion
tensor images at baseline and their variations during
the follow up.
Analysis of fMRI data: Active and RS fMRI data will
be pre-processed using SPM12. Activations during the
Go/no-Go task will be estimated using SPM12. An inde-
pendent Component Analysis (ICA) will be used to de-
compose RS fMRI data into spatially independent maps
and time courses, using the GIFT software [71]. Individ-
ual functional maps will be converted to Z-scores before
entering group statistics, to obtain voxel values compar-
able across subjects. A systematic process will be applied
to inspect and select the components of interest from
the estimated ones. The association of each component
spatial map with a priori probabilistic maps of GM,
WM, and CSF within the MNI space will contributed to
identifying the components with a signal change corre-
lated to the GM. Components with a high correlation
with cerebrospinal fluid or WM, or with a low correl-
ation with the GM, will be excluded. In addition, to
identify components with potentially functional rele-
vance, a frequency analysis of IC time courses will be
performed to detect those with a high (50% or greater)
spectral power at a low frequency (between 0.01 and
0.05 Hz) [72]. The spatial patterns of the remaining ICs
will be sorted out on the basis of their matching with
relevant RSNs found in previous studies [73–76] A seed-
base RS functional connectivity (RS FC) analysis, using
the thalami as a seed, will also be performed to assess
modifications of RS FC of the thalamic network in the
main study groups and their correlations with clinical
scales [77].
Standardisation and data quality
To promote data quality, all assessment activites are
manualised. Further, before initiating recruitment all
PI’s, blinded and unblinded assessors participated in a
training session at which all of the tests were dis-
cussed and demonstrated. Following this, every site
performed a rehearsal incremental CPET on at least
one MS patient and sent the data to the responsible
PI for review. To ensure that all sites initialise their
accelerometers correctly, the assessors themselves
wore a device for 7 days, and the data sent to the
same PI for review. Similarly, a mock MRI scan will
occur at the four centers participating in the MRI
substudy. All data will be entered into REDCap [78].
Before entering any data in the actual study database,
all assessors will undertake practice lessons and
complete a practice certification consisting of a set of
ficticious data. Data will be downloaded regularly for
quality control purposes and basic reports will be
generated via the REDCap system and SAS. Data
forms will employ validation and skip pattern logic
that provides constrained input whenever possible. Er-
rors or questionable data will be turned into data
queries and will be sent by the Data Coordinating
Center to the sites for correction and/or clarification.
Reports will be produced and include information on
data quality, completeness and protocol adherence.
Confidentiality is guaranteed through anonymity. Each
participant is given an unique case number, and the
Data Coordinating Center at Washington University are
not given any identifying data.
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Power analysis
The primary outcome measure is the SDMT. A four-
point improvement on the SDMT is considered clinically
useful [37, 38]. Evidence for the reliability of the test was
initially obtained in a study of 80 adults administered
the test in 2 test sessions approximately 30 days [79].
Comparisons of test scores obtained at times 1 and 2 re-
sulted in a test-retest correlation of 0.80. Individuals
tested at baseline obtained a score of 56.79 ± 9.84. Scores
increased an average of 3.67 points to 60.46 ± 11.16 at
retesting. Such an increase in scores at the second test
reflects a “practice effect,” which is commonly seen in
test-retest situations [80]. This level of test-retest correl-
ation has been reproduced multiple times and is often
higher. We expect a learning curve to be present in all
groups and this will in effect wash out in the analyses as
our comparisons will utilize comparative changes in
means.
Camp et.al. in a primary progressive population stud-
ied longitudinally revealed standard deviations of 13.96
at baseline, 15.24 at 1 year and 14.32 at 2 years [81].
Sonder et.al. showed a standard deviation of 14.3. Fur-
ther, the change over time was generally impacted
slightly by the learning curve returning to baseline as the
time scale extended [82]. Thus, we can think of changes
from baseline to 12 weeks or 6 months in the present
study as potentially representing a zero change except
for the intervention effect.
The reliability of the SDMT is high, 0.80 or higher as
noted above, implying that the correlation between two
measures that are not materially changing have high reli-
ability and thus the standard deviation of the change
should be relatively small. If we assume that the correl-
ation between two measures is only 0.50, then our esti-
mated standard deviation of the change would be the
same as the cross-sectional value (i.e. 10 to 16). How-
ever, given the high test-retest correlation, we should as-
sume the correlation between the measures is higher.
Assuming it is 0.80, then the estimated standard devi-
ation would be between 6.3 and 10.1 (assuming the
cross-sectional standard deviation is 10 or 16 respect-
ively). Thus assuming a standard deviation of the
changes of 7 to 8, seems reasonable and 8 may be
slightly high, since 16 is at the upper end of most re-
ports. If the standard deviation is 12 cross-sectionally,
then the estimated change standard deviation is 7.6.
Nevertheless, for sample size estimation it is better to be
a bit conservative.
We propose to treat four groups of participants as
noted above. We estimated our sample size using a
standard 1-factor analysis of variance approach with a
Type I error set at 5%. We computed the sample size ne-
cessary to achieve 80% power for such a design assuming
conservative changes. For simplicity we used 4 points for
the combined treatments, assuming that we want to
demonstrate a clinically meaningful difference on aver-
age and that the two interventions are additive; 4 more
correct answers has been suggested by the FDA as a
meaningful change [37]. We also assumed a change of 2
answers for each of the single interventions and 0 for
the sham group [83]. (Note again that the learning curve
and practice effects will contribute equally to each group
and the results shown below are the same if we had
chosen 6, 4, 4, 2 or other combinations with the same
relative spread to accommodate the practice effects, etc.)
Table 6 shows that with 90 participants per treatment
group at the time of analysis, there is over 80% power to
detect differences as specified (4,2,2,0) across the four
groups when the standard deviation of the change is 8
points and the overall Type I error to detect any mean
differences is 0.05.
In order to assess the sensitivity of these calculations
to assumptions, we conducted a few additional patterns
of response and standard deviations. Clearly for any
standard deviation smaller than 8, we have more power.
For example, if the standard deviation of the change
were 7 instead of 8, the power is 91% with 90 patients
per group and 81% with 70 per treatment group. If the
treatment difference pattern is 4,1,1,0; the power is 86%
with four groups assuming a standard deviation of 8.
If the change is less in the combined treatment group,
and the pattern is say 3,2,1,0 and a standard deviation of
the change is 8, the power is 59%. If the pattern is 3,2,1,
0 and the standard deviation of the change is 7, then the
power is 71%. Thus, the power is reasonably high for a
variety of the patterns. Obviously increasing the sample
size in each treatment group increases the power, but
we will increase the number recruited and randomized
Table 6 Power for 4 group Analysis of Variance with mean
changes in the SDMT of 4 more correct for the combined
group; 2 more correct for each of the single intervention
groups and 0 change for the Sham Group
Power n Total N
0.52751 50.00 200
0.57247 55.00 220
0.61476 60.00 240
0.65423 65.00 260
0.69081 70.00 280
0.72449 75.00 300
0.75533 80.00 320
0.78341 85.00 340
0.80885 90.00 360
0.83179 95.00 380
0.85239 100.00 400
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to account for potential dropouts, thus should have
ample power under these assumptions.
Statistical analyses
The statistical analyses will begin with descriptive ana-
lyses of baseline characteristics (age, sex, disease dur-
ation, EDSS, other physiologic parameters at baseline
and over time, medications, etc.), by treatment allocation
((1) EX + CR, (2) EX + CR-S (3) EX-S + CR or (4) EX-
S + CR-S). Continuous variables will be summarized
using the statistics mean, median, SD, minimum and
maximum. Categorical variables will be summarized
with frequency counts and percentages. During the trial,
drop-outs and losses to follow-up will be compared be-
tween groups to ensure high follow-up rates and com-
parability and that no particular demographic or site is
differentially dropping out of one treatment group. The
currently supported version of SAS software will be used
to perform all data analyses.
Summary tables will indicate the number of subjects
with complete data for each measurement, event or out-
come. All analyses will be based on available data, unless
otherwise stated, and the intent-to-treat principle. Sec-
ondary analyses will examine the per protocol analysis
population. All confidence intervals will be two-sided
and will use 95% confidence levels. Any analyses requir-
ing significance testing will use a two-sided test at the
5% significance level, unless otherwise specified.
Differences in baseline characteristics between groups
will be examined in continuous variables, such as age
and disease duration using an ANOVA and categorical
variables using a Chi-square tests of association. Inform-
ative censoring will be examined with potentially biased
imputation and non-informative censoring as well as
missing-at random assumptions using multiple imput-
ation to provide sensitivity analyses of the primary
results.
The primary analysis will utilize an ANOVA and in-
clude an interaction term for the combined treatments.
A priori contrasts (stated above in the hypothesis sec-
tion) will be conducted if the overall test of differences
amongst the treatment groups achieves statistical signifi-
cance. For the pairwise comparisons Dunnett’s test will
be used to preserve the Type I error rate. Additional
analyses will be conducted as sensitivity analyses using
Analysis of Covariance (ANCOVA). These will include
site, gender, age and other covariates that may be seen
to differ amongst the groups at baseline. Multiple imput-
ation will be used to assess the sensitivity of the primary
results to dropouts.
Secondary outcomes will be similarly assessed using
ANOVA and ANCOVA procedures and, repeated mea-
sures mixed models will be used for measurements that
are taken between baseline and 12 weeks.
Statistical analysis of MRI data
In each group, longitudinal hierarchical linear models
will be used to assess changes over time of WM tract
DTI measures and average Z-scores of RS functional
connectivity (FC), accounting for the repeated measure-
ment design. Statistical analyses of VBM, TBM, MRI ac-
tive and RS FC maps derived from ICA will be
performed using the SPM12 software (whole brain ana-
lysis, p < 0.05, family-wise error [FWE], corrected for
multiple comparisons).
Voxelwise differences of MD, RD, AD and FA values
between groups at baseline, and their within-group
changes at follow up will be tested using a permutation
method (“Randomize” program within FSL) and two-
sample and paired t tests, as appropriate (p < 0.05 FWE).
Linear regression analysis (using SPM12) will be used
to assess the correlations between fMRI activations, RS
FC maps and clinical and neuropsychological data.
Discussion
The present study will be the first combined CR and ex-
ercise trial to date in persons with PMS with the poten-
tial to change clinical practice; this trial further is the
largest combined CR and exercise study in any MS
phenotype. As the study is a large international multi-
center study, efforts have been made to ensure trial
feasibility. Moreover, the collaborating sites have access
to patient populations that should allow sufficient re-
cruitment. Efforts have been made to ensure optimal
standardization and subsequently best possible data
quality. Such efforts relate to 1) comprehensive and de-
tailed assessment and intervention manuals as well as a
combination of face-to-face and distance training on
how to deliver these, 2) weekly quality control and feed-
back of the delivered interventions, 3) hotlines in case of
questions relating to delivery of the interventions and 4)
weekly telephone conferences allowing the widely dis-
persed centers close communication.
There are well described challenges related to the de-
velopment of appropriate sham interventions when it
comes to exercise trials [84, 85]. Adding to this chal-
lenge is the fact that the underlying mechanisms mediat-
ing potential exercise induced effects on brain function
are poorly understood [86]. A sham-concept that does
not significantly improve cardio-respiratory function but
still involves attentional and social contact components
was therefore chosen as a counterweight to the aerobic
exercise intervention [13]. Choosing the appropriate
sham treatment is important as it limits the potential of
this intervention to alter brain function that is known to
accompany aerobic exercise.
The imaging component to our study broadens the
scope of our inquiry. MRI techniques are currently being
applied to investigate mechanisms related to structural
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and functional brain plasticity in healthy individuals fol-
lowing training and in neurologically impaired individ-
uals following spontaneous recovery and after
rehabilitation interventions. Several authors have used
fMRI during active tasks or at rest to evaluate the effects
of motor [87, 88] and cognitive [18, 36, 89–92] rehabili-
tation in MS patients. All of these studies have demon-
strated that a modulation of function in brain regions
have a crucial role in the trained function which occurs
in MS after rehabilitation and is associated with clinical
improvement. Whether such changes are possible in
people with PMS, is not yet known. Our study therefore
has the potential to address the dearth of data in this
population and shed light on the degree to which neural
plasticity is retained in the context of a progressive dis-
ease course.
The impact of cognitive dysfunction in the lives of
people with MS is considerable. It is associated with dif-
ficulties finding and sustaining employment, maintaining
intimate relationships and friendships, pursuing leisure
activities and managing basic activities of daily living
[93]. Given that we have chosen a primary outcome
measure, namely the SDMT, in which a 10% (or 4-point)
change over time is known to be clinically significant,
should our interventions achieve this threshold, they will
acquire the imprimatur of an elusive ecological validity.
Moreover, the multinational composition of the research
teams all pursuing a shared methodology has the poten-
tial to demonstrate that the chosen interventions can
transcend language, cultural and indeed institutional
barriers that make it difficult to extrapolate results from
only a single centre.
The study is expected to conclude by the end of 2022.
With a robust sample size that ensures adequate statis-
tical power, the findings, if positive, have the potential to
guide clinically meaningful interventions for people with
PMS who struggle with all the functional limitations as-
sociated with slowed processing speed.
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